300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Financial Services
Construction
Oil and Gas
Mobile
Retail
Payments
Film
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Faroe Islands
Tunisia
Taiwan
Zimbabwe
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
South Korea
Oman
Poland
Puerto Rico
Armenia
Guernsey
Cameroon
Colombia
China
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
New Zealand
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Seychelles
Botswana
Paraguay
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Peru
Mongolia
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
CN Innovations, VC Fund

CN Innovations

VC Fund

Hong Kong, Hong Kong

CN Innovations is a science-based technology and precision engineering company. CN Innovations Holdings provides OEM technical and supply chain solutions to major industries.

Total investments:
5
Last investment:
Lead investor:
20%

Last updated:

Industries CN Innovations invests in

EnergyMedicalBiopharmaFuel CellWearables

Stages CN Innovations invests in

SeedSeries ASeries BVenture - Series Unknown

Countries CN Innovations invests in

Hong KongUnited StatesUnited Kingdom

Investment Focus

Industry

  • Energy 1 (20%)
  • Medical 1 (20%)
  • Biopharma 1 (20%)
  • Fuel Cell 1 (20%)
  • Wearables 1 (20%)
See all 17 industries →

Stage

  • Seed 2 (40%)
  • Series A 1 (20%)
  • Series B 1 (20%)
  • Venture - Series Unknown 1 (20%)

Country

  • Hong Kong 1 (20%)
  • United States 1 (20%)
  • United Kingdom 1 (20%)

Investments

CompanyDescriptionRoundLinks
CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based onthe culture of primary human hepatocytes in the company’s proprietary LiverChip® platform. The HBV disease model, which is referred to as Quantum-B®, is currently being deployed in drug discovery and research alliances with a number of leading pharmaceutical and biotech companies.Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next generation organ-on-chips which will improve the quality of life for millions of people around the world by fast tracking breakthrough therapies to market. $21M / Series B / Apr 23, 2024
Versogen develops electrolyzer technology for water and renewable energy to produce green hydrogen at scale. The company produces high-performing hydroxide exchange membranes for a variety of applications, such as lowering the production costs of fuel cells and reducing industrial carbon emissions, and laying the foundation for a sustainable energyfuture. $14.5M / Series A / May 10, 2022
CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based onthe culture of primary human hepatocytes in the company’s proprietary LiverChip® platform. The HBV disease model, which is referred to as Quantum-B®, is currently being deployed in drug discovery and research alliances with a number of leading pharmaceutical and biotech companies.Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next generation organ-on-chips which will improve the quality of life for millions of people around the world by fast tracking breakthrough therapies to market. $9M / Venture - Series Unknown / Mar 02, 2020
Redefining the mobile computing experience through screen-free, voice and gesture-based products and services. $510K / Seed / Jan 10, 2017
CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based onthe culture of primary human hepatocytes in the company’s proprietary LiverChip® platform. The HBV disease model, which is referred to as Quantum-B®, is currently being deployed in drug discovery and research alliances with a number of leading pharmaceutical and biotech companies.Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next generation organ-on-chips which will improve the quality of life for millions of people around the world by fast tracking breakthrough therapies to market. Seed

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Financial Services
Construction
Oil and Gas
Mobile
Retail
Payments
Film
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Faroe Islands
Tunisia
Taiwan
Zimbabwe
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
South Korea
Oman
Poland
Puerto Rico
Armenia
Guernsey
Cameroon
Colombia
China
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
New Zealand
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Seychelles
Botswana
Paraguay
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Peru
Mongolia
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does CN Innovations invest in?

CN Innovations invests primarily in Energy, Medical and Biopharma startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in Hong Kong. The Investment Focus section breaks down every industry, stage and country in the portfolio.

When did CN Innovations last invest?

The most recent investment recorded for CN Innovations closed in Apr 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
CN Innovations CN Innovations Find emails